The numbers say recovery, but the perspective from Main Street is not as optimistic.

FORBES: Who's Right, Traders Or Analysts?

However, while it's certainly true that the panel addressed the future of some two-dozen painkillers, the main focus--from a financial perspective--was on three of these pills.

FORBES: The FDA's Conflict Of Interest Problem